12879_2022_7076_MOESM1_ESM.docx (47.66 kB)
Additional file 1 of Clinical outcomes after treatment with direct antiviral agents: beyond the virological response in patients with previous HCV-related decompensated cirrhosis
journal contribution
posted on 2022-01-28, 04:30 authored by Georges-Philippe Pageaux, Clovis Lusivika Nzinga, Nathalie Ganne, Didier Samuel, Céline Dorival, Fabien Zoulim, Carole Cagnot, Thomas Decaens, Dominique Thabut, Tarik Asselah, Philippe Mathurin, François Habersetzer, Jean-Pierre Bronowicki, Dominique Guyader, Isabelle Rosa, Vincent Leroy, Olivier Chazouilleres, Victor de Ledinghen, Marc Bourliere, Xavier Causse, Paul Cales, Sophie Metivier, Véronique Loustaud-Ratti, Ghassan Riachi, Laurent Alric, Moana Gelu-Simeon, Anne Minello, Jérôme Gournay, Claire Geist, Albert Tran, Armand Abergel, Isabelle Portal, Louis d’Alteroche, François Raffi, Hélène Fontaine, Fabrice Carrat, Stanislas PolAdditional file 1: Table S1. Balance of baseline covariates following IPTW analysis according to DAA exposure. Table S2. Summary of non-liver related deaths by cause. Table S3. Summary of liver related deaths by cause. Table S4. Factors associated with HCC, all-cause mortality, and liver transplant in all 559 patients included for study. Table S5. Characteristics of hepatocellular carcinoma according to DAA exposure. Table S6. Incidence rates of hepatocellular carcinoma, all-cause mortality, liver-related mortality, non-liver-related mortality, and liver transplant in all 559 patients under study according to DAA exposure period and virological response status. Table S7. Incidence rates of hepatocellular carcinoma, all-cause mortality, liver-related mortality, non-liver-related mortality, and liver transplant in all 55 patients with a Meld score>20 or Child-Pugh score C according to DAA exposure period and virological response status.
